- Benzinga•7 hours ago
Following AstraZeneca plc (ADR) (NYSE: AZN )’s strong start to 2017, including a positive data report for breast cancer treatment Lynparza, investors await a barrage of news highlighting significant findings ...
- American City Business Journals•yesterday
AstraZeneca entered into an agreement to sell the rights to a cancer drug in the United States and Canada to TerSera Therapeutics for an upfront payment of $250. The deal could also net AstraZeneca up to $70 million in sales-related income if revenue milestones are met, along with recurring quarterly sales-based payments that are set at a mid-teen percent of product sales. TerSera Therapeutics, which has offices in Iowa and Illinois, acquired the rights to Zoladex, an injectable drug used to treat prostate cancer, breast cancer and certain benign gynaecological disorders.
- Investor's Business Daily•5 days ago
Pfizer and Tesaro could follow AstraZeneca which, early Friday, unveiled strong results from a trial of Lynparza in breast cancer.
AZN.L : Summary for ASTRAZENECA PLC ORD SHS $0.25 - Yahoo Finance
AstraZeneca PLC (AZN.L)
LSE - LSE Delayed Price. Currency in GBp
Add to watchlist
|Bid||4,490.00 x 6100|
|Ask||4,630.00 x 13000|
|Day's Range||4,495.00 - 4,612.77|
|52 Week Range||3,680.00 - 5,505.00|
|PE Ratio (TTM)||16.51|
|Dividend & Yield||2.80 (4.97%)|
|1y Target Est||N/A|